SEATTLE, Dec. 7 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the Company has promoted Mark Frohlich, M.D. to the position of senior vice president of clinical affairs and chief medical officer. Dr. Frohlich, a urologic oncologist with over a decade of oncology drug development and patient treatment experience in the public and private sectors, was instrumental to the filing of the company's Biologics License Application (BLA) for PROVENGE(R) (sipuleucel-T) and has also had responsibility for monitoring the progress of the company's ongoing Phase 3 IMPACT trial (D9902B), a pivotal trial for Dendreon, the results of which could support the licensure of PROVENGE. Dr. Frohlich was promoted from the position of vice president of clinical affairs.
"Mark has been an exemplary leader who has led Dendreon's clinical efforts during a very active time for the organization with the ongoing regulatory approval process of PROVENGE -- a process which Mark and the rest of our team remain committed to seeing through to the approval of this promising immunotherapy for prostate cancer," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We are fortunate to have someone with Mark's expertise at the helm of our clinical team with the depth of his experience in oncology as well as his direct patient experience."
Prior to joining Dendreon in 2005, Dr. Frohlich was vice president and
medical director at Xcyte Therapies where he oversaw its medical affairs
operations. At Xcyte, he led the clinical development program for an
autologous activated T cell therapy for the treatment of cancer, infection
and immunodeficiency. Before that, he was an assistant professor in the
Division of Hematology/Oncology at the University of California, San
Francisco, where he specialized in urologic oncology and was active in
laboratory, translational and clinical research. While at the University of
California, San Franc
|SOURCE Dendreon Corporation|
Copyright©2007 PR Newswire.
All rights reserved